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ABSTRACT The alarming rise in antibiotic resistance has led to an increase in patient mortality and health care costs. This prob-
lem is compounded by the absence of new antibiotics close to regulatory approval. Acinetobacter baumannii is a human patho-
gen that causes infections primarily in patients in intensive care units (ICUs) and is highly antibiotic resistant. Colistin is one of
the last-line antibiotics for treating A. baumannii infections; however, colistin-resistant strains are becoming increasingly com-
mon. This cationic antibiotic attacks negatively charged bacterial membranes in a manner similar to that seen with cationic anti-
microbials of the innate immune system. We therefore set out to determine if the increasing use of colistin, and emergence of
colistin-resistant strains, is concomitant with the generation of cross-resistance to host cationic antimicrobials. We found that
there is indeed a positive correlation between resistance to colistin and resistance to the host antimicrobials LL-37 and lysozyme
among clinical isolates. Importantly, isolates obtained before and after treatment of individual patients demonstrated that colis-
tin use correlated with increased resistance to cationic host antimicrobials. These data reveal the overlooked risk of inducing
cross-resistance to host antimicrobials when treating patients with colistin as a last-line antibiotic.
IMPORTANCE Increased use of the cationic antibiotic colistin to treat multidrug-resistant Acinetobacter baumannii has led to the
development of colistin-resistant strains. Here we report that treatment of patients with colistin can induce not only increased
resistance to colistin but also resistance to host cationic antimicrobials. This worrisome finding likely represents an example of a
broader trend observed in other bacteria against which colistin is used therapeutically such as Pseudomonas aeruginosa and
Klebsiella pneumoniae. Furthermore, these data suggest that the possible future use of an array of cationic antimicrobial pep-
tides in development as therapeutics may have unintended negative consequences, eventually leading to the generation of hyper-
virulent strains that are resistant to innate host defenses. The potential for the induction of cross-resistance to innate immune
antimicrobials should be considered during the development of new therapeutics.
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Due to overuse and misuse of antibiotics and the ability ofbacteria to rapidly gain resistance, we are now in an age of
multidrug-resistant (MDR) and pan-drug-resistant (PDR) bacte-
rial pathogens and face a possible return to the pre-antibiotic era.
The burden of antimicrobial resistance has increased the length of
hospital stays, patient mortality, and health care costs (1–5). Acin-
etobacter baumannii is a Gram-negative and highly antibiotic-
resistant bacterial pathogen (6, 7). Due to its ability to persist on
surfaces for weeks, its ability to colonize humans, and its increas-
ing rate of antibiotic resistance, A. baumannii has become an
emerging health care problem (6, 8).
Polymyxin antibiotics, including colistin, are currently used as
last-line drugs to treat MDR A. baumannii infections (9). Colistin
is a cationic antimicrobial peptide that disrupts both the outer and
inner membranes of Gram-negative bacteria (10), a trait shared by
the host cationic antimicrobials LL-37 and lysozyme (11–16).
LL-37 is a human antimicrobial peptide typically found at sites of
inflammation, where it is a primary defense against Gram-
negative bacteria (17). Lysozyme is a host antimicrobial found
within multiple immune cells as well as in secretions such as tears,
breast milk, and mucus and is important for their activity against
invading microbes. Importantly, the highly cationic, nonenzy-
matic, C-terminal portion of lysozyme has very potent antimicro-
bial activity (12–14).
Given the increasing prevalence of colistin resistance among
A. baumannii clinical isolates (9), we set out to test whether there
was a correlation with cross-resistance to host cationic antimicro-
bials. We assembled a panel of A. baumannii isolates (CI-1, CI-2,
CI-3, 17978, CI-4, ARLC, MU134, MU215, MU181, and MU52)
and first determined their colistin MICs (see Table S1 in the sup-
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plemental material) and susceptibilities to multiple other antibi-
otics (Table S2). Bacterial suspensions were prepared using a
PROMPT (3M Company, St. Paul, MN) inoculation system, and
antibiotic susceptibilities were determined using Neg Breakpoint
Combo Panel type 41 on a Microscan WalkAway Plus automated
system (Siemens Healthcare Diagnostics Inc., West Sacramento,
CA). Additionally, the MICs for colistin were measured using
Etest strips (bioMérieux, Durham, NC), following the inoculation
and reading instructions of the manufacturer. The strains exhib-
ited a range of MIC values. Using Clinical and Laboratory Stan-
dards Institute (CLSI) interpretive criteria, we found that strains
CI-1, CI-2, CI-3, and 17978 were sensitive to colistin whereas
CI-4, ARLC, MU134, MU215, MU181, and MU52 were resistant
(Table S1).
We treated the colistin-sensitive and -resistant isolates with
LL-37 or lysozyme to determine their sensitivities, as previously
described (18). Briefly, overnight cultures were grown from fro-
zen stock in lysogeny broth (LB; also known as Luria broth) (BD
Biosciences, Sparks, MD) at 37°C with aeration and then diluted
to a final concentration of ~10e6 CFU/ml in 25% LB. Bacteria
FIG 1 Colistin resistance correlates with resistance to host cationic antimicrobials in A. baumannii clinical isolates. (A to J) Colistin-sensitive (A to D) and
colistin-resistant (E to J) A. baumannii clinical isolates were treated with 6.25 g/ml of LL-37 (green) or 2.5 mg/ml of lysozyme (blue) for the indicated times and
plated for enumeration of CFU. Time zero CFU is indicated by dashed black lines. (K to L) Percent changes of CFU from time zero to 2 h after treatment with
LL-37 (K) or lysozyme (L) from 4 individual experiments with 3 to 4 samples of each isolate represented in panels A to J. Data were analyzed for significance using
the unpaired Student’s t test. **, P  0.001; ***, P  0.0001. Error bars represent the standard deviations of the results determined for triplicate samples.
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were treated with host antimicrobials (LL-37, 6.25 g/ml; lyso-
some, 2.5 mg/ml) and incubated with aeration at 37°C, and ali-
quots were plated at 0 h, 1 h, and 2 h for enumeration of CFU. The
colistin-sensitive clinical isolates CI-1 (Fig. 1A) and CI-2 (Fig. 1B)
were inhibited from replicating to wild-type levels in the presence
of LL-37, while CI-3 (Fig. 1C) and 17978 (Fig. 1D) were killed. In
contrast, the colistin-resistant clinical isolates CI-4 (Fig. 1E),
ARLC (Fig. 1F), MU134 (Fig. 1G), MU215 (Fig. 1H), MU181
(Fig. 1I), and MU52 (Fig. 1J) each replicated roughly 100- to 200-
fold after 2 h in the presence of LL-37. These data suggest that
colistin resistance correlates with increased resistance to the host
cationic antimicrobial peptide LL-37, which was further clearly
demonstrated when results from 4 experiments performed with
the aforementioned strains were pooled (Fig. 1K). We observed
similar phenotypes following lysozyme treatment, with the excep-
tion of the colistin-susceptible 17978 isolate (Fig. 1D), which was
able to persist in the presence of lysozyme instead of being killed,
and CI-2 (Fig. 1B), which exhibited very limited replication. These
results were again further illustrated when data from several ex-
periments were pooled (Fig. 1L) and suggest that colistin resis-
tance is highly correlated with resistance to lysozyme.
We next investigated the basis for the resistance phenotypes
observed. The A. baumannii PmrAB two-component regulatory
system induces phosphoethanolamine modifications to the lipid
A component of lipopolysaccharide (LPS) in response to the pres-
ence of polymyxins (19, 20). Arroyo et al. showed that point mu-
tations within the PmrB periplasmic domain, histidine kinase
(HisK) dimerization/phosphoacceptor domain, or C-terminal
ATP binding domain (ATPB) can confer constitutive polymyxin
resistance through these lipid A modifications (20). We sequenced
the pmrB genes in the colistin-resistant isolates used in this study
and found that each harbored nonsynonymous mutations in the
sequences encoding one or more of these three domains com-
pared to the pmrB sequence from the colistin-sensitive 17978
strain (see Table S1 in the supplemental material). In contrast,
only synonymous mutations were identified in the sequences of
pmrB from the colistin-sensitive strains. Nonsynonymous point
mutations conferring resistance can be selected rapidly and likely
explain the ability of some of the colistin-sensitive strains to even-
tually acquire resistance during extended exposure to LL-37 or
lysozyme (see Fig. S1A to D in the supplemental material) (20).
Taken together, these data suggest that mutations within pmrB
confer not only colistin resistance but also cross-resistance to host
cationic antimicrobial peptides.
Since the clinical isolates used here were very diverse (isolated
from different anatomical sites, from different areas of the United
States, and exhibiting differing antibiotic susceptibility patterns;
see Table S1 and S2 in the supplemental material), it is not sur-
prising that there was heterogeneity in their patterns of resistance
to host antimicrobials; specifically, the colistin-sensitive CI-2 iso-
FIG 2 Clinical treatment with colistin can induce increased resistance to host cationic antimicrobials. Sequential A. baumannii isolates were collected from 2
patients (Ab6266 and Ab6267, patient 1; Ab3527 and Ab3941, patient 2) pre-colistin treatment (Ab6266 and Ab3527) and post-colistin treatment (Ab6267 and
Ab3941). Isolates were treated with 6.25 g/ml of LL-37 (A and C) or 2.5 mg/ml of lysozyme (B and D). Percent changes from time zero to 2 h after treatment
with host antimicrobials from 3 experiments with 3 to 4 samples of each isolate are represented. Data were analyzed for significance using the unpaired Student’s
t test. *, P  0.05; **, P  0.001. Error bars represent the standard deviations of the results determined for triplicate samples.
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late displayed low-level resistance to LL-37 and lysozyme (Fig. 1B)
that was not observed with the other colistin-sensitive isolates
(Fig. 1A and C to D). In order to overcome the complications of
comparing diverse strains, and to directly determine whether
colistin treatment can induce cross-resistance to host cationic an-
timicrobials, we obtained 2 pairs of A. baumannii clinical isolates
from patients pre- and post-colistin treatment (21). Each pair of
serial isolates (Ab6266 and Ab6267, and Ab3527 and Ab3941) was
from a distinct patient, under 35 years of age, who had sustained
severe trauma overseas (21). Ab6267 was collected after 3 weeks of
patient treatment with colistin, and Ab3941 was collected after
6 weeks of patient treatment with colistin. Both pre-treatment
isolates (Ab6266 and Ab3527) were colistin sensitive, while the
post-treatment isolates (Ab6267 and Ab3941) displayed increased
resistance to colistin (see Table S1 in the supplemental material).
In addition, the transition to increased colistin resistance was not
accompanied by changes in susceptibility to the other antibiotics
tested (Table S2). While we cannot specify the event(s) (an in-
duced mutational event, selection for a preexisting mutant, or
reinfection) that led to the selection for the post-treatment resis-
tant isolates, the pre- and post-treatment isolates were shown to
be highly similar by pulse-field gel electrophoresis (PFGE), using a
90% similarity cutoff, compared to 1,500 A. baumannii strains
collected from 24 geographically separate hospitals (21). Addi-
tionally, optical genome mapping (OGM) analysis showed that
the two sets of pre- and post-treatment isolates shared 99%
homology (21).
When treated with LL-37 or lysozyme, the post-colistin treat-
ment Ab6267 isolate displayed a significant increase in resistance
compared to the corresponding pre-colistin treatment isolate
(Ab6266) (Fig. 2A and B). Ab3941 displayed a significant increase
in resistance to killing by lysozyme compared to Ab3527 (Fig. 2D),
although there was no change in its level of resistance to LL-37
(Fig. 2C). Neither pre-colistin treatment isolate demonstrated re-
sistance to LL-37 or lysozyme over 22 h of treatment (see Fig. S1E
and F in the supplemental material). As with the colistin-resistant
isolates tested above, the post-colistin treatment strains both har-
bored nonsynonymous mutations in critical PmrB domains (Ta-
ble S1). These data from sequentially isolated strains pre- and
post-colistin treatment strongly support the conclusion that clin-
ical use of colistin induces cross-resistance to host cationic anti-
microbial peptides.
Implications. The rising prevalence of antibiotic resistance is
linked to increases in mortality, morbidity, length of hospitaliza-
tion, and health care costs (1–5). Understanding the mechanisms
and consequences of antimicrobial resistance is critical to our
ability to combat this problem. Here we have determined that
there is a strong correlation between colistin resistance and cross-
resistance to the host antimicrobials LL-37 and lysozyme (Fig. 1
and 2). This is likely a phenomenon that occurs broadly and is
relevant to a range of nosocomial pathogens, including Pseudomo-
nas aeruginosa and Klebsiella pneumoniae, against which colistin is
used as a therapy. This is also critical information in light of the
fact that numerous cationic antimicrobial peptides are currently
in development as novel therapeutics (22–24). Our data caution
that the use of such agents in the clinic may have the unintended
negative consequence of inducing resistance to host antimicrobi-
als, which could lead to the selection of hypervirulent strains in the
long term.
SUPPLEMENTAL MATERIAL
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